Sugi Predict

Sugi Predict / Compounds / SCHEMBL20146043

SCHEMBL20146043

SCHEMBL20146043

COC(=O)c1ccc(Br)c(C)c1C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 3/20 0.44
▸ CA2 P00918 3/20 0.44
▸ CA9 Q16790 3/20 0.44
▸ CA12 O43570 2/20 0.44
▸ CA7 P43166 2/20 0.44
▸ CA14 Q9ULX7 2/20 0.44
▸ PDK2 Q15119 1/20 0.44
▸ PDK4 Q16654 1/20 0.44
▸ NR4A2 P43354 4/20 0.42
▸ LMNA P02545 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ GAA P10253 3/20 0.42
▸ KDM4E B2RXH2 3/20 0.42
▸ GLA P06280 2/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ HSD17B10 Q99714 2/20 0.42
▸ ATM Q13315 2/20 0.42
▸ MAPT P10636 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ CASP1 P29466 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3422644 0.87 CA12 (0.54) CA1CA2CA9CA12CA7
SCHEMBL1028047 0.86 CA1 (0.43) CA1CA2CA9CA12CA7
SCHEMBL979279 0.85 CA1 (0.46) CA1CA2CA9CA12CA7
SCHEMBL25606874 0.85 CA1 (0.46) CA1CA2CA9CA12CA7
SCHEMBL977363 0.83 KDM4E (0.44) CA1CA2CA9CA12CA7
SCHEMBL16035010 0.83 SOS1 (0.44) CA1CA2CA9CA12CA7
SCHEMBL31135335 0.83 SOS1 (0.44) CA1CA2CA9CA12CA7
SCHEMBL2472606 0.83 KDM4E (0.46) CA1CA2CA9CA12CA7
SCHEMBL22219524 0.83 SOS1 (0.44) CA1CA2CA9CA12CA7
SCHEMBL6535286 0.83 KDM4E (0.41) CA1CA2CA9CA12CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4371982-A2 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS RQX Pharmaceuticals, Inc. (US) 2024-05-22 — — EP disclosed
WO-2024079072-A1 NEW N-HETEROARYLBENZAMIDES DERIVATIVES AS FLT3 INHIBITORS BIODOL THERAPEUTICS (FR) 2024-04-18 — — WO disclosed
EP-4353712-A1 NEW N-HETEROARYLBENZAMIDES DERIVATIVES AS FLT3 INHIBITORS Biodol Therapeutics (FR) 2024-04-17 — — EP disclosed
EP-3583096-B1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS RQX PHARMACEUTICALS INC (US) 2024-03-27 — — EP disclosed
CN-117321046-A Indazole-based compounds and related methods of use 阿维纳斯企业公司 2023-12-29 — — CN disclosed
US-20230133667-A1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS RQX PHARMACEUTICALS INC (US) 2023-05-04 — — US disclosed
US-20230133667-A1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS RQX PHARMACEUTICALS INC (US) 2023-05-04 — — US disclosed
US-20230133667-A1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS RQX PHARMACEUTICALS INC (US) 2023-05-04 — — US disclosed
US-20230097358-A1 INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2023-03-30 — — US disclosed
CN-110520413-B Macrocyclic broad spectrum antibiotics 阿奇克斯制药公司 2023-02-17 — — CN disclosed
EP-3929194-A1 SUBSTITUTED NITROGEN CONTAINING COMPOUNDS Bristol-Myers Squibb Company (US) 2021-12-29 — — EP disclosed
US-20210198316-A9 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) 2021-07-01 — — US disclosed
US-10857155-B2 Compounds targeting proteins, compositions, methods, and uses thereof BIOTHERYX, INC. (US) 2020-12-08 — — US disclosed
CN-109456253-B Method for synthesizing (S) -3- (4-bromophenyl) -piperidine or salt thereof through chiral induction 上海博璞诺科技发展有限公司 2020-04-07 — — CN disclosed
CN-109456253-B Method for synthesizing (S) -3- (4-bromophenyl) -piperidine or salt thereof through chiral induction 上海博璞诺科技发展有限公司 2020-04-07 — — CN disclosed
CN-110698388-A Method for industrially producing (S) -3- (4-bromophenyl) piperidine 暨明医药科技（苏州）有限公司 2020-01-17 — — CN disclosed
US-10406165-B2 Compounds targeting proteins, compositions, methods, and uses thereof BIOTHERYX, INC. (US) 2019-09-10 — — US disclosed
US-20180264000-A1 COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF BIOTHERYX, INC. 2018-09-20 — — US disclosed
WO-2018169777-A1 COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF BIOTHERYX, INC. (US) 2018-09-20 — — WO disclosed
EP-2970106-B1 BORON-CONTAINING DIACYLHYDRAZINES INTREXON CORP (US) 2018-05-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180264000-A1 COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF GSPT1, GSPT2, GGT1 CA1 1373/4885CA2 1349/4885CA9 3384/4885
US-20210198316-A9 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS MRPL21, PEPD, CTSC CA1 4337/4885CA2 4501/4885CA9 4280/4885
US-20230097358-A1 INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE LRRK2, CRBN, MDM2 CA1 4169/4885CA2 4388/4885CA9 4839/4885
US-20230133667-A1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS MRPL21, PEPD, CTSC CA1 4337/4885CA2 4501/4885CA9 4280/4885
US-10857155-B2 Compounds targeting proteins, compositions, methods, and uses thereof GSPT1, GSPT2, GGT1 CA1 1373/4885CA2 1349/4885CA9 3384/4885
US-10406165-B2 Compounds targeting proteins, compositions, methods, and uses thereof GSPT1, GSPT2, GGT1 CA1 1373/4885CA2 1349/4885CA9 3384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.